109 related articles for article (PubMed ID: 33667587)
1. High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: From a randomized phase III trial.
Pen SL; Shan YS; Hsiao CF; Liu TW; Chen JS; Ho CL; Chou WC; Hsieh RK; Chen LT; Ch'ang HJ
Radiother Oncol; 2021 May; 158():146-154. PubMed ID: 33667587
[TBL] [Abstract][Full Text] [Related]
2. Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected Pancreatic Adenocarcinoma but Not Which Patients Are Suited for Additional Adjuvant Chemoradiation Therapy: From a Prospective Randomized Study.
Chiu YF; Liu TW; Shan YS; Chen JS; Li CP; Ho CL; Hsieh RK; Hwang TL; Chen LT; Ch'ang HJ;
Int J Radiat Oncol Biol Phys; 2023 Sep; 117(1):74-86. PubMed ID: 37055279
[TBL] [Abstract][Full Text] [Related]
3. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma.
Xu HX; Li S; Wu CT; Qi ZH; Wang WQ; Jin W; Gao HL; Zhang SR; Xu JZ; Liu C; Long J; Xu J; Ni QX; Yu XJ; Liu L
Pancreatology; 2018 Sep; 18(6):671-677. PubMed ID: 30153903
[TBL] [Abstract][Full Text] [Related]
4. Krüppel-like factor 10 modulates stem cell phenotypes of pancreatic adenocarcinoma by transcriptionally regulating notch receptors.
Tsai YC; Cheng KH; Jiang SS; Hawse JR; Chuang SE; Chen SL; Huang TS; Ch'ang HJ
J Biomed Sci; 2023 Jun; 30(1):39. PubMed ID: 37308977
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient Selection.
Naffouje SA; Sabesan A; Kim DW; Carballido E; Frakes J; Hodul P; Denbo JW; Malafa M; Fleming J; Hoffe S
J Gastrointest Surg; 2022 Feb; 26(2):376-386. PubMed ID: 34506031
[TBL] [Abstract][Full Text] [Related]
6. Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation.
Herman JM; Jabbour SK; Lin SH; Deek MP; Hsu CC; Fishman EK; Kim S; Cameron JL; Chekmareva M; Laheru DA; Narang AK; Pawlik TM; Hruban RH; Wolfgang CL; Iacobuzio-Donahue CA
Pancreas; 2018 Feb; 47(2):208-212. PubMed ID: 29329157
[TBL] [Abstract][Full Text] [Related]
7. Krüppel-like Factor 10 as a Prognostic and Predictive Biomarker of Radiotherapy in Pancreatic Adenocarcinoma.
Tsai YC; Hsin MC; Liu RJ; Li TW; Ch'ang HJ
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958386
[TBL] [Abstract][Full Text] [Related]
8. Chemoradiotherapy after curative surgery for locally advanced pancreatic cancer: A 20-year single center experience.
Weibel P; Pavic M; Lombriser N; Gutknecht S; Weber M
Surg Oncol; 2021 Mar; 36():36-41. PubMed ID: 33285435
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic ductal adenocarcinoma.
Murata Y; Mizuno S; Kishiwada M; Uchida K; Noguchi D; Gyoten K; Hayasaki A; Fujii T; Iizawa Y; Tanemura A; Kuriyama N; Sakurai H; Isaji S
Pancreatology; 2021 Dec; 21(8):1482-1490. PubMed ID: 34452821
[TBL] [Abstract][Full Text] [Related]
10. Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma.
Turan N; Benekli M; Unal OU; Unek İT; Tastekin D; Dane F; Algın E; Ulger S; Eren T; Topcu TO; Turkmen E; Babacan NA; Tufan G; Urakci Z; Ustaalioglu BO; Uysal OS; Ercelep OB; Taskoylu BY; Aksoy A; Canhoroz M; Demirci U; Dogan E; Berk V; Balakan O; Ekinci AŞ; Uysal M; Petekkaya İ; Ozturk SC; Tonyalı Ö; Çetin B; Aldemir MN; Helvacı K; Ozdemir N; Oztop İ; Coskun U; Uner A; Ozet A; Buyukberber S;
Chin J Cancer Res; 2015 Aug; 27(4):408-16. PubMed ID: 26361410
[TBL] [Abstract][Full Text] [Related]
11. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
[TBL] [Abstract][Full Text] [Related]
12. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma.
Bachet JB; Maréchal R; Demetter P; Bonnetain F; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; Vaillant JC; André T; Closset J; Salmon I; Emile JF; Van Laethem JL
Ann Oncol; 2012 Sep; 23(9):2327-2335. PubMed ID: 22377565
[TBL] [Abstract][Full Text] [Related]
13. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base.
Rutter CE; Park HS; Corso CD; Lester-Coll NH; Mancini BR; Yeboa DN; Johung KL
Cancer; 2015 Dec; 121(23):4141-9. PubMed ID: 26280559
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: A propensity score-matched analysis of a nationwide clinical oncology database.
Ecker BL; McMillan MT; Datta J; Lee MK; Karakousis GC; Vollmer CM; Drebin JA; Fraker DL; Roses RE
Cancer; 2017 May; 123(6):967-976. PubMed ID: 28263387
[TBL] [Abstract][Full Text] [Related]
15. Protocol of the PANCALYZE trial: a multicenter, prospective study investigating the tumor biomarkers CXCR4, SMAD4, SOX9 and IFIT3 in patients with resected pancreatic adenocarcinoma to predict the pattern of recurrence of the disease.
Popp FC; Popp MC; Zhao Y; Betzler C; Kropf S; Garlipp B; Benckert C; Kalinski T; Lippert H; Bruns CJ
BMC Cancer; 2017 Mar; 17(1):229. PubMed ID: 28356064
[TBL] [Abstract][Full Text] [Related]
16. Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy.
Murata Y; Hamada T; Kishiwada M; Ohsawa I; Mizuno S; Usui M; Sakurai H; Tabata M; Ii N; Inoue H; Shiraishi T; Isaji S
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):413-25. PubMed ID: 21898089
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy followed by concurrent chemoradiation is associated with improved survival for resected stage I-II pancreatic cancer.
Ma SJ; Hermann GM; Prezzano KM; Serra LM; Iovoli AJ; Singh AK
Cancer Med; 2019 Mar; 8(3):939-952. PubMed ID: 30652417
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC).
Kamarajah SK; Bundred JR; Alrawashdeh W; Manas D; White SA
HPB (Oxford); 2020 May; 22(5):649-659. PubMed ID: 31894014
[TBL] [Abstract][Full Text] [Related]
19. Krüppel-like factor 10 expression as a prognostic indicator for pancreatic adenocarcinoma.
Chang VH; Chu PY; Peng SL; Mao TL; Shan YS; Hsu CF; Lin CY; Tsai KK; Yu WC; Ch'ang HJ
Am J Pathol; 2012 Aug; 181(2):423-30. PubMed ID: 22688058
[TBL] [Abstract][Full Text] [Related]
20. Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I-II or unresected stage III pancreatic cancer.
Ma SJ; Iovoli AJ; Hermann GM; Prezzano KM; Singh AK
Cancer Med; 2019 Aug; 8(9):4110-4123. PubMed ID: 31183965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
